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Abstract 
Background :To assess the prevalence of essential 
hypertension and evaluate cardiovascular risk in 
patients in Pakistan. 
Methods:This cross-sectional, non-interventional 
study was conducted at multiple centres throughout 
Pakistan. Data was collected from patients of either 
gender, ≥18 years of age, seeking routine medical 
consultation. Diagnosis and staging of hypertension 
was carried out using guidelines laid by Seventh 
Report of Joint National Committee (JNC 7). Gender-
wise Framingham scores were calculated based on 
non-laboratory and laboratory parameters.  
Results: Out of 2336 patients evaluated, prevalence 
of hypertension and prehypertension was 51.5%  and 
31.4% , respectively. A total of 501 patients had co-
prevalent diabetes and hypertension. Ten-year 
Framingham scores calculated using non-laboratory 
parameters showed 56% (947/1693) patients aged ≥30 
years were at medium-to-high risk for cardiovascular 
disease (CVD). While Framingham scores based on 
laboratory or non-laboratory parameters were not 
significantly different for men, in women the non-
laboratory based score was higher. Angiotensin-
converting enzyme inhibitors and calcium channel 
blockers were antihypertensive agents of choice. 
Conclusions: Since prevalence of pre-
hypertension and hypertension in Pakistani adults 
continues to be on rise and substantial proportion of 
study population is at medium-to-high risk of 
developing CVD within the next 10 years, regular BP 
monitoring and risk scoring is mandated for 
identification of at-risk population and optimal 
management of CVD.  
Key  Words:Hypertension, Physicians, Primary 
care. 
Introduction 
Hypertension is an independent risk factor for 
coronary heart disease, heart failure, cerebrovascular 
disease, and chronic renal failure and a leading cause 
of cardiovascular (CV) morbidity and mortality. 1,2 
Over 2/3rd of patients with hypertension are from 
developing countries and this is attributed to modern 
lifestyles and increasing life spans. The global burden 
of hypertension is predicted to cross 1.5 billion by 
2025.3-5  
Hypertension is widely prevalent in Pakistan and the 
number of cases has doubled from 17% in 1980 to 35% 
in 2008. 6 Results from Pakistan National Health 
Survey in the late nineties showed that incidence of 
hypertension in adults >45 years of age (33%) was 
twice that in the general population (≥15 years and 
older; 18%). 7 In addition, approximately 1/4th of 
middle-aged adults in Pakistan have coronary artery 
disease and 17% population carries at least two 
associated risk factors. 8,9 
Since hypertension is a progressive disease, early 
detection and blood pressure control are the keys to 
reduction in CV risk. Clinical evidence demonstrates 
that screening for high blood pressure has benefits in 
reduction of CV events.10 Guidelines laid down by the 
7th report of the Joint National Committee on 
Detection, Evaluation, and Treatment of High Blood 
Pressure (JNC 7) recommends screening individuals 
≥18 years of age for hypertension, and evaluating 
those with hypertension for associated CV risk factors. 
2 In recent years, rapid and significant changes in 
lifestyle practices in Pakistan have a direct bearing on 
CV risk. Consequently, there is an urgent need to 
determine the burden of hypertension as well as the 
associated CV risk in Pakistani adults.  
 
Risk prediction models are a useful tool in clinical 
practice to identify, communicate with, and treat high-
risk individuals before disease complications set in. 
Numerous risk factors interact and contribute to the 
pathology of CV disease. Epidemiological and clinical 
evidence suggest that translating risk factors into 
scores can predict an individual’s CV risk with a 
certain amount of accuracy.Risk prediction algorithms 
such as Framingham Risk Score (FRS), Systematic 
Coronary Risk Evaluation (SCORE), and World Health 
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Organisation/International Society of 
Hypertension(WHO/ISH) score are widely used to 
identify and manage patients at high CV risk. 1,11,12 The 
Framingham model employs either laboratory 
parameters (such as serum lipid levels) or non-
laboratory parameters (such as body mass index and 
anthropometrics) for calculation of risk score. A 
comparative study published in the Lancet in 2008 
showed that scoring with non-laboratory parameters 
not only identifies patients at risk, but also offers the 
advantages of feasibility and cost-effectiveness.13  
Laboratory investigations in Pakistan are generally 
expensive to conduct and can be an economic strain to 
a majority of the population, especially those in the 
low-income strata. Hence, a risk scoring model that 
combines predictability with practicality and can be 
used in primary care physicians’ (PCP) clinic would be 
quite useful in CV risk estimation in Pakistan. 
Focusing on these issues, the primary goal of our 
study was to assess prevalence of hypertension in 
general population visiting PCPs for medical 
consultation. In addition, we also sought to compare 
non-laboratory based parameters over standard 
laboratory parameters in predicting CV risk in adults 
≥30 years of age, to stratify our hypertensive patients 
as per JNC 7 guidelines and to assess the 
antihypertensive therapy prescribed to them.  
 
Patients and Methods 
This was a national, cross-sectional, multicenter 
hypertension registry conducted between November 
to October 2014 at 140 sites in 12 cities in Pakistan. 
Study investigators were community-based PCPs from 
these cities and were randomly selected from the 
physician database of Sanofi-Aventis Pakistan Ltd. 
The study was conducted in compliance with all 
international and applicable guidelines, national laws 
and regulations of Pakistan. The study was conducted 
in the ambulatory care setting, at individual outpatient 
clinics.Adults ≥18 years of age, who were  seeking 
medical consultation with their PCP, irrespective of 
their hypertension status were included. Patients with 
a past history of myocardial infarction or objectively 
confirmed angina pectoris, suspected/known 
secondary hypertension, or were pregnant, were 
excluded. Each investigator recruited 20 consecutive 
patients.  
Data collected by the investigator at the time of 
enrolment included patient demographics and 
anthropometrics, lifestyle choices, CV risk factors and 
medical history, and two consequent blood pressure 
recordings taken at the site at a 5-minute interval. 
Patients ≥30 years of age were directed to a 
predetermined laboratory for estimation of serum 
cholesterol and high-density lipoprotein (HDL). 
Laboratory tests were conducted by Aga Khan 
University Hospital Clinical Laboratory.Prevalence 
estimation and staging of hypertension were done 
using JNC 7 guidelines. Hypertension was 
characterized as systolic blood pressure (SBP) ≥140 
mmHg or diastolic blood pressure (DBP) ≥90 mmHg 
for patients without diabetes, and SBP ≥130 mmHg or 
DBP ≥80 mmHg for patients with diabetes. For each 
patient ≥30 years,Framingham risk scores were 
calculated (Models A and B, Suppl. Fig. 1 and 2) based 
on their laboratory and non-laboratory parameters. 
Scores for each patient were multiplied by a factor of 
1.4 as recommended by the National Institute for 
Health and Care Excellence (NICE) in order to make 
them applicable to the South Asian phenotype. 14 
Based on an estimated prevalence of hypertension of 
18% with a 1.5% margin of error, 95% confidence level 
and anticipating 10% data unworthiness (due to 
incomplete information, missing forms, etc.) a sample 
size of 2800 patients was required. This sample size 
also allowed us to meaningfully evaluate CV risk with 
both Framingham models with a 95% confidence limit 
and 1.5% margin of error. Differences between scores 
generated by Model A and B were probed for 
statistical validity by paired t-test. Patients’ scores 
were also categorized for risk as low (<10%), medium 
(10%-20%), or high (>20%) and differences in 
proportion within each category were compared using 
Chi-square testThe statistical analyses were performed 
using SPSS version 18 (SPSS Inc., Chicago, USA) 
 
Results 
 The study population comprised 56% males and had 
an average age of 40.813.1 years (Table 1). The 
proportion of patients ≥30 years in the cohort was 
72.5% (1693/2336. BMI at 28.25.1 kg/m2 was 
marginally higher in this subpopulation, as was the 
proportion of patients with BMI ≥25 kg/m2. In patients 
≥30 years, the proportion of women with BMI ≥25 
kg/m2 was greater than men (78.0% vs. 67.8%). This 
trend was replicated in the case of prevalence of 
diabetes i.e29.4% (497/1693) patients ≥30 years had 
diabetes and a larger proportion of women presented 
with diabetes (32.1% versus 26.9% in men). The 
proportion of smokers in patients ≥30 years was 21.3% 
(n=363). Average cholesterol and fasting HDL levels in 
these patients were 192.945.0mg/dL and 44.612.8 
mg/dL, respectively. 
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As per JNC 7 guidelines, 51.5%(n=1202, 95%  CI. 48.6% 
- 54.4%)of patients in our study had hypertension. 
Average SBP and DBP in the overall cohort was 
137.521.1 mmHg and 87.611.3 mmHg respectively, 
and both were marginally higher in patients ≥30 years 
SBP: 141.920.7 mmHg; DBP: 89.710.7mmHg. The 
study population had 31.4%patients with 
prehypertension, 29.9% patients with Stage 1 
hypertension, and 26.0% patients with Stage 2 
hypertension. Staging of hypertension in diabetes 
versus non-diabetes showed that a substantially higher 
proportion of patients with diabetes were either in pre-
hypertensive stage or had hypertension when 
compared to patients without diabetes (96.3% versus 
84.7%; Table 2). The incidence of diabetes in 
hypertensive patients was 47.1% (501/1202) in 
comparison to 3.0% (34/1134) in normotensive 
patients. The prevalence of hypertension in non-
diabetic patients was 30% (C.I. 28.2 – 31.9) while the 
prevalence of hypertension in patients with 
diabeteswas 21.4% (C.I. 19.8 – 23.2). (Table 2).Mean 
Framingham score in women calculated using non-
laboratory parameters (Model A;18.19.1) was 
significantly higher than that estimated using 
laboratory parameters Model B; mean score: 14.87.4; 
paired mean difference: 3.174.27; p<0.01; (Table 3). In 
men, mean scores were 16.38.3 with Model A and 
16.985 with Model B with a paired mean difference of 
-0.683.4 (p<0.01). The use of individual Framingham 
scores for risk stratification showed disparate results 
in women (Table 3). Model B indicated 62.7% (n=502) 
and 8.9% (n=71) women in the low-risk and the high-
risk category, respectively. In comparison, Model A 
calculated 45.6% (n=366) and 25.3% (n=203) women in 
low- and high-risk categories, respectively (p<0.01). In 
contrast, both Model A and B showed a similar 
proportion of men in either of the risk categories. At 
the time of enrolment, 84% (1014/1202) of patients 
with hypertension were prescribed antihypertensive 
medications (Table 4). The most widely prescribed 
class of agents was angiotensinogen-converting 
enzyme (ACE) inhibitors (in 41% [493/1202] patients). 
Of the 734 patients in the pre-hypertensive stage, 251 
(34.2%) were prescribed antihypertensive agents. Of 
139 patients with co-prevalent prehypertension and 
diabetes, 57% (n=80) were prescribed antihypertensive 
agents. The agents of choice in patients with co-
prevalent diabetes and hypertension were ACE 
inhibitors and beta blockers.  
 
 
Table 1. Patient Characteristics 
Characteristics 
Total study population 
(n=2336) 
Patients ≥30 years of age 
(n=1693) 
 n (%) Mean (SD) n (%) Mean (SD) 
Age, in years  40.8 (±13.1)  46.6 (±10.4) 
Gender 
     Male 1307 (56.0)  892 (52.7)  
     Female 1029 (44.0)  801 (47.3)  
Height, in cms  163.5 (±10.6) 
 162.7 
(±10.5) 
Weight, in kg  72.9 (±13.5)  74.1 (±13.0) 
BMI, in kg/m2  27.4 (±5.3)  28.2 (±5.1) 
Patient with 
BMI ≥25 
kg/m2 
1530 (65.5)  
1231 (72.7) 
 
Blood pressure, in mmHg 
SBP  137.5 (±21.1) 
 141.9 
(±20.7) 
DBP  87.6 (±11.3)  89.7 (±10.7) 
Hip 
circumference, 
in cms 
 101.0 (±14.6) 
 
103.6 
(±14.4) 
Waist Hip 
Ratio (WHR), 
overall 
 0.93 (±0.10) 
 
0.94 (±0.10) 
     WHR males   0.95 (±0.09)  0.95 (±0.09) 
 WHR females   0.91 (± 0.10)  0.92 (± 0.10) 
Truncal Obesity 
     Males with 
WHR ≥0.90 
957 (41.0)  701 (41.4)  
  Females with 
WHR  ≥0.80 
928 (39.7)  743 (43.9)  
Pre-existent 
diabetes 
535 (22.9)  497 (29.4) 
 
Smoking 513 (22.0)  363 (21.4)  
Total cholesterol ;192.9 (45.0) 
<160   329 (19.4)  
160-199   620 (36.6)  
200-239   422 (24.9)  
240-279   134 (7.9)  
≥280   62 (3.7)  
Fasting HDL;44.6 (12.8) 
≥60   139 (8.2)  
50-59   255 (15.1)  
45-49   251 (14.8)  
35-44   670 (39.6)  
<35   252 (14.9)  
SD – standard deviation; BMI – body mass index; SBP – systolic 
blood pressure; DBP – diastolic blood pressure; HDL – high density 
lipoprotein; SD – standard deviation 
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Table 2. Prevalence and staging of 
hypertension as per JNC 7 guidelines 
Prevalence  (N = 2336) 
 BP cut-off ranges Prevalence  
  n % (95% CI) 
Non-diabetic 
patients  
SBP≥140 or DBP≥90 701 
30.0 
 (28.2 – 31.9) 
Diabetic 
patients  
SBP≥130 or DBP≥80 501 
21.4  
(19.8 – 23.2) 
Staging n (%) 
Total Study Population (N = 2336)  
Normal*  295 (12.6) 
Prehypertension†  734 (31.4) 
Stage 1 Hypertension‡  699 (29.9) 
Stage 2 Hypertension∫  608 (26.0) 
   
Non-diabetic patients ≥18 yrs  (N = 
1801)  
  
Normal*  275 (15.3) 
Prehypertension†  595 (33.0) 
Stage 1 Hypertension‡  505 (28.0) 
Stage 2 Hypertension∫  426 (23.7) 
   
Diabetic patients ≥18 yrs (N = 535)   
Normal*  20 (3.7) 
Prehypertension†  139 (26.0) 
Stage 1 Hypertension‡  194 (36.3) 
Stage 2 Hypertension∫  182 (34.0) 
   
*Normal:SBP <120 mmHg and DBP <80 mmHg;† Prehypertension:SBP 120–
139 mmHg or DBP 80–89 mmHg;‡ Stage 1 Hypertension: SBP 140–159 mmHg 
or DBP 90–99 mmHg;∫ Stage 2 Hypertension: SBP ≥160 mmHg or ≥100 
mmHg;JNC 7 – Seventh Report of the Joint National Committee in Prevention, 
Detection, Evaluation and Treatment of High Blood Pressure;BP – blood 
pressure;SBP – systolic blood pressure; DBP – diastolic blood pressure; CI – 
confidence interval 
Table 3. Gender-based Framingham scores (A) and 
risk stratification (B) using non-laboratory & 
laboratory predictors in patients aged ≥30 years 
(n=1693) 
(A) Framingham scores 
 Non-
laboratory 
predictors 
(Model A) 
Laboratory 
predictors 
(Model B) 
Paired Mean 
Difference 
(±SD) 
p-value 
Females, N = 801     
Mean total score (SD) 18.1 (± 9.1) 14.8 (± 7.4) 
3.17 (± 4.27) <0.01 
Range -4 to 45 -6 to 39 
     
Males, N = 892     
Mean total score (SD) 16.3 (± 8.3) 16.9 (± 8.5) 
-0.68 (± 3.4) <0.01 
Range -3 to 39 0 to 41 
     
(B) Risk stratification 
Risk category Score n(%)  
Non-
laboratory 
predictors 
(Model A) 
Laboratory 
predictors 
(Model B) 
p-value 
Female, N = 801     
Low: < 10% ≤ -2 to 12 366 (45.6) 502 (62.7) <0.01 
Medium: 10%-20% 13 to 17 232 (28.9) 228 (28.4) 0.59 
High: >20% 18 to ≥21 203 (25.3) 71 (8.9) <0.01 
     
Male, N = 892     
Low: < 10% ≤ -3 to 10 380 (42.6) 367 (41.1) 0.53 
Medium: 10%-20% 11 to 14 213 (23.9) 222 (24.9) 0.62 
High: >20% 15 to ≥18 299 (33.5) 303 (34.0) 0.84 
 SD – standard deviation 
Table  4. Therapeutic management according to 
stage of hypertension 
Treatment 
prescribed 
Hypertensives without 
diabetes 
Hypertensives with diabetes 
n (%) n (%) 
Prehyper
tension 
n=734 
Stage 1 
n=699 
Stage 2 
n=608 
Prehyp
ertensi
on 
n=139 
Stage 1 
n=194 
Stage 2 
n=182 
Angiotensin 
Converting 
Enzyme 
Inhibitors 
67 (9.1)  269 (38.5) 277 (45.6) 
30 
(21.6) 
79 (40.7) 
81 
(44.5) 
Calcium 
Channel 
Blockers 
53 (7.2) 154 (22.0) 191 (31.4) 
22 
(15.8) 
32 (16.5) 
44 
(24.2) 
Angiotensin 
Receptor 
Blockers 
45 (6.1) 140 (20.0) 141 (23.2) 
21 
(15.1) 
44 (22.7) 
48 
(26.4) 
Beta 
Blockers 
36 (4.9) 113 (16.2) 139 (22.9) 
16 
(11.5) 
54 (27.8) 
61 
(33.5) 
Diuretics 
12 (1.6) 68 (9.7) 108 (17.8) 4 (2.9) 29 (14.9) 
40 
(22.0) 
Fixed Dose 
Combination  
32 (4.4) 60 (8.6) 73 (12.0) 13 (9.4) 24 (12.4) 
28 
(15.4) 
Others 6 (0.8) 21 (3.0) 36 (5.9) 2 (1.4) 7 (3.6) 12 (6.6) 
 
Discussion 
In this nationwide estimate of the burden of essential 
hypertension in Pakistani adults, we discovered that 
prevalence of hypertension in outpatient settings is 
substantially higher than in previous population-based 
surveys, and every second patient ≥18 years of age 
visiting a primary care physician (PCP) is likely to 
have high blood pressure. After staging patients’ 
blood pressureas per JNC 7, we determined that only 
12.6% of our study population was normotensive and 
this proportion further decreased to 3.7% in patients 
with diabetes. Furthermore, analysis of Framingham 
scores revealed that >50% of the study population was 
at a medium-to-high risk of developing CV events 
within the next 10 years. The rising prevalence of 
hypertension in Pakistan has been attributed to a 
plethora of factors like genetic predisposition, 
urbanization, dietary habits, concomitant rise in 
prevalence of obesity and diabetes, sedentary 
lifestyles, and lack of health awareness.15,16  Our 
estimated prevalence of 51.4% is substantially higher 
than figures reported from previous studies in 
Pakistan, South Asia, the United States, and Europe. 
However, we must consider that since our study was 
conducted in clinical settings,the study cohort could 
have a higher proportion of hypertensive patients than 
the general population.  4,6,7,17 
Prehypertension is defined as SBP of 120-139 mmHg 
or DBP of 80-89 mmHg per the JNC 7 guidelines and is 
a precursor stage to hypertension. 2 Approximately 
1/3rd of pre-hypertensive patients are estimated to 
progress to hypertensive stage within 4 
years.18Prehypertension, by itself, is also associated 
with adverse CV outcomes and progression of 
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diabetes. 19,20 Hence, it becomes imperative to also 
monitor the prevalence of prehypertension and 
suggest appropriate intervention as per guidelines. 
Various elaborate global studies such as the NHANES 
or a meta-analysis by Guo, et al estimate the global 
burden of prehypertension to be 31%-36%. 21,22 Our 
study population had 31.4% patients in the pre-
hypertensive stage, which corroborates with the global 
estimate. Additionally, the prevalence of 
prehypertension in our study is comparable to those 
estimated from other regional studies in Asia – India, 
Korea, Japan, China, and Iran.23-26  
The United Kingdom Prospective Diabetes Study 
determined that hypertension is comorbid in 
approximately 70% of patients with diabetes, and is 
twice as prevalent in patients with diabetes. 28 A 
sizeable proportion of newly diagnosed diabetes 
patients have also been shown to have pre-existent 
hypertension. In our study, approximately 1/5th of the 
patients (n=501, 21.4%; CI: 19.8 – 23.2) had co-
prevalent diabetes and hypertension, and 701 (30.0%, 
CI: 28.2 – 31.9) patients had hypertension exclusively. 
The prevalence of diabetes in hypertensive patients 
was 41.7% . These findings are consistent with the 
belief that hypertension can worsen diabetic 
complications and strongly corroborate the association 
of hypertension and diabetes in CV pathology.  
Despite proven usefulness of aforementioned risk 
prediction models, issues that have most likely 
hindered their routine use in clinical practice at a PCP 
level in Pakistan are awareness of these models among 
the physicians’ community and the need for expensive 
and time-consuming laboratory tests to implement 
these. There is limited data on the applicability of 
these models in a population that is as heterogeneous 
in terms of ethnicity, lifestyle, socioeconomic status, 
and genetics, as in Pakistan. A recent study that 
compared these models (FRS, SCORE, and WHO/ISH) 
in Malaysian population suggests use of FRS for 
identifying individuals at high risk. 29 In our study, 
non-laboratory Framingham scores indicated a higher 
risk profile in females in comparison with laboratory-
based scores, with a paired difference of 3.174.27 
between the average scores (p<0.01). In contrast, risk 
profiles were similar for males when either model was 
used. However, almost a quarter of Pakistani women 
and approximately one-third of Pakistani men over the 
age of 30 years are at a high risk of developing 
cardiovascular disease within the next 10 years. Thus, 
our results demonstrate utility of non-laboratory based 
Framingham risk scoring for identification of high CV 
risk individuals in Pakistan and validate similar 
findings from other studies. 13,30-32  
The Pakistan Hypertension League has drafted 
guidelines for therapeutic management of 
hypertension in Pakistan and these are largely based 
on those laid by the National Institute for Health and 
Care Excellence (United Kingdom). These recommend 
the use of ACE inhibitors, ARBs or CCBs as first line of 
treatment depending on the patients’ age (ACE 
inhibitors or ARBs for patients < 55 years and CCBs 
for patients > 55 years) and ethnicity and are in stark 
contrast with the JNC 7 guidelines which advocate use 
of thiazide diuretics for lowering BP. In our study we 
observed an adherence to the Pakistani guidelines, 
since ACE inhibitors were the drugs of choice across 
the hypertensive fraction of the study cohort. 
Interestingly, despite 31.4%  of the study cohort being 
pre-hypertensive, we discerned that only 1/3rd of them 
were prescribed antihypertensive medications. In pre-
hypertensive patients with diabetes, only 57%  were 
prescribed medical intervention. This is indeed 
alarming since JNC 7 guidelines specify pre-
hypertension with diabetes to be a compelling 
indication that warrants the use of BP-lowering agents 
to ameliorate disease progression. 2 
Conclusion 
1. Prevalence of hypertension in clinical settings in 
Pakistan is undesirably high and these patients are at a 
significant risk of developing cardiovascular disease.  
2.This major health issue needs to be addressed by a 
concerted effort from the medical community and 
governmental authorities. 
3 Current national guidelines need to be harmonized 
with latest evidence-based guidelines to increase 
disease awareness and optimize treatments.   
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